These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3922441)

  • 41. Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients.
    Prasad A; Rampling RP; Glover V; Sandler M
    Psychiatry Res; 1987 Oct; 22(2):111-6. PubMed ID: 3685221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine.
    Reynolds GP; Riederer P; Rausch WD
    J Neural Transm Suppl; 1980; (16):173-8. PubMed ID: 6776236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease).
    Jenike MA
    Am J Psychiatry; 1985 Jun; 142(6):763-4. PubMed ID: 4003602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
    Raft D; Davidson J; Wasik J; Mattox A
    Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Baker GB; Sowa B; Todd KG
    J Psychiatry Neurosci; 2007 Sep; 32(5):313-5. PubMed ID: 17823646
    [No Abstract]   [Full Text] [Related]  

  • 46. Human platelet monoamine oxidase--a useful enzyme in the study of psychiatric disorders?
    Fowler CJ; Tipton KF; MacKay AV; Youdim MB
    Neuroscience; 1982 Jul; 7(7):1577-94. PubMed ID: 6956813
    [No Abstract]   [Full Text] [Related]  

  • 47. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.
    Reynolds GP; Riederer P; Sandler M
    J R Soc Med; 1981 Sep; 74(9):649-52. PubMed ID: 7288807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Blood MAO/DBH index and the results of the treatment of endogenous depression].
    Puzyński S; Hauptmann M; Rode A; Kalinowski A; Bidzińska E; Beresewicz M; Bidziński A
    Psychiatr Pol; 1990; 24(3):202-8. PubMed ID: 2084728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of whole blood serotonin and platelet MAO in children with schizophrenia and major depressive disorder.
    Rogeness GA; Mitchell EL; Custer GJ; Harris WR
    Biol Psychiatry; 1985 Mar; 20(3):270-5. PubMed ID: 3978162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelet MAO-B and endogenous MAO-A inhibitory activity in depressed patients: stability with electroconvulsive treatment.
    Moriearty PL; Herrick C; Shafey M; Bornstein P; Becker RE
    Biol Psychiatry; 1987 Sep; 22(9):1155-8. PubMed ID: 3651533
    [No Abstract]   [Full Text] [Related]  

  • 52. Platelet MAO deamination of serotonin in depressed patients. Changes after imipramine treatment and clinical correlations.
    Quintana J
    Biol Psychiatry; 1988 Jan; 23(1):44-52. PubMed ID: 3337854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine.
    Davidson J; McLeod MN; White HL
    Am J Psychiatry; 1978 Apr; 135(4):470-2. PubMed ID: 345826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoamine Oxidase as a Potential Biomarker of the Efficacy of Treatment of Mental Disorders.
    Uzbekov MG
    Biochemistry (Mosc); 2021 Jun; 86(6):773-783. PubMed ID: 34225599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?
    Mendis N; Pare CM; Sandler M; Glover V; Stern GM
    Psychopharmacology (Berl); 1981; 73(1):87-90. PubMed ID: 6785797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet monoamine oxidase activity in elderly depressed outpatients.
    Schneider LS; Severson JA; Pollock V; Cowan RP; Sloane RB
    Biol Psychiatry; 1986 Dec; 21(14):1360-4. PubMed ID: 3790624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoamine oxidase activity in platelets before and after sleep deprivation as predictor for antidepressive drug response.
    Fähndrich E; Müller-Oerlinghausen B
    Mod Probl Pharmacopsychiatry; 1983; 19():327-36. PubMed ID: 6865972
    [No Abstract]   [Full Text] [Related]  

  • 59. Platelet MAO activity and age at onset of depression in elderly depressed women.
    Alexopoulos GS; Lieberman KW; Young RC; Shamoian CA
    Am J Psychiatry; 1984 Oct; 141(10):1276-8. PubMed ID: 6486267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.